PITTSBURGH, May 20, 2005 /PRNewswire-FirstCall via COMTEX/ -- Mylan Laboratories Inc. (NYSE: MYL) today announced the appointment of John Deiriggi to the new position of Vice President of Generic Business Development. In this role Deiriggi will have responsibility for generic business development at all Mylan Laboratories subsidiaries.

Deiriggi is a 19 year veteran of Mylan, serving most recently as Vice President of Strategic Planning, where he was responsible for strategic evaluation, selection, prioritization and execution of new generic products to be developed by Mylan as well as project management of all outsourced generic products developed through alliances with external partners. Deiriggi originally joined Mylan as an analytical chemist and has held leadership positions in research and development, quality control and purchasing during his distinguished career. He holds a B.S. degree in biology from the University of West Virginia.

Robert J. Coury, Mylan's Vice Chairman and Chief Executive Officer commented, "John is a valuable member of the Mylan team with extensive experience and a deep knowledge of the generic industry. He will increase our focus on strengthening Mylan's organic generic platform by expanding external opportunities through alliances, joint ventures, and acquisitions which strategically align Mylan's generic business goals with the overall direction of the company."

John Deiriggi commented, "I am extremely excited to have this opportunity to help drive the ongoing success of Mylan's generic business. I've witnessed incredible growth in generics during my tenure at Mylan, and I believe we can achieve significant additional growth in the years ahead as consumers increasingly recognize the quality and cost savings of generic products."

Mylan Laboratories Inc. is a leading pharmaceutical company with four subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., UDL Laboratories, Inc. and Mylan Bertek Pharmaceuticals Inc., that develop, license, manufacture, market and distribute an extensive line of generic and proprietary products.

For more information about Mylan, visit www.mylan.com .

This press release includes statements that constitute "forward-looking statements", including with regard to the anticipated growth and future success of the Company. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward- looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the effects of vigorous competition on the commercial acceptance of the Company's products and their pricing; the Company's exposure to lawsuits, regulatory and legislative changes and other contingencies associated with its business outside the control of management; and the other risks detailed in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

SOURCE Mylan Laboratories Inc.

Media, Patrick Fitzgerald, or Investors, Kris King, both of Mylan Laboratories Inc., +1-724-514-1800